Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice

References

• Repatha^® (evolocumab) injection, for subcutaneous use [package insert]Thousand Oaks, CAAmgen2015
   Google Scholar
• Praluent^® (alirocumab) injection, for subcutaneous use [package insert]Bridgewater, NJSanofi-Aventis2017
   Google Scholar
• GoldbergACGiddingSSKnowing the prevalence of familial hyper-cholesterolemia mattersCirculation2016133111054105726976913
   PubMed Web of Science ®Google Scholar
• ReinerZManagement of patients with familial hypercholesterolemiaNat Rev Cardiol2015121056557526076948
   PubMed Web of Science ®Google Scholar
• van den HeuvelTWCohenAFRissmanREuropean drug market entries 2015 with new mechanisms of actionClin Med (Lond)201616547548027697814
   PubMed Web of Science ®Google Scholar
• LiCLinLZhangWEfficacy and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trialsJ Am Heart Assoc201546e00193726077586
   PubMed Web of Science ®Google Scholar
• Cainzos-AchiricaMMartinSSCornellJEMulrowCDGuallarEPCSK9 inhibitors: a new era in lipid-lowering treatment?Ann Intern Med20151631646525915768
   PubMed Web of Science ®Google Scholar
• The Wall Street Journal [homepage on the Internet]Silverman E. New cholesterol meds may lower heart risks, but will they break the bank?Wall Street Journal2015320 Available from: https://blogs.wsj.com/pharmalot/2015/03/20/new-cholesterol-meds-may-lower-heart-risks-but-will-they-break-the-bank/Accessed July 10, 2017
   Google Scholar
• ArrietaAPageTFVeledarENasirKEconomic evaluation of PCSK9 inhibitors in reducing cardiovascular risk from health system and private payer perspectivesPLoS One2017121e016976128081164
   PubMed Web of Science ®Google Scholar
• KaziDSMoranAECoxsonPGCost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular diseaseJAMA2016316774375327533159
   PubMed Web of Science ®Google Scholar
• National Center for Health StatisticsHealth, United States, 2015: With Special Feature on Racial and Ethnic Health DisparitiesHyattsville, MD2016
   Google Scholar
• Health Affairs Blog [homepage on the Internet]ShrankWLotvinASinghSBrennanTIn the debate about cost and efficacy, PCSK9 inhibitors may be the biggest challenge yetHealth Affairs Blog2015217 Available from: http://healthaffairs.org/blog/2015/02/17/in-the-debate-about-cost-and-efficacy-pcsk9-inhibitors-may-be-the-biggest-challenge-yet/Accessed July 10, 2017
   Google Scholar
• MehrSRWill the PCSK9 inhibitors be employers’ “line in the sand”?Am Health Drug Benefits20169317117427606041
   PubMedGoogle Scholar
• U.S. Food and Drug Administration, Center for Drug Evaluation and ResearchThe Endocrinologic and Metabolic Drugs Advisory Committee Meeting. Briefing document: BLA 125559. Praluent (ali-rocumab) injectionFDA2015 Available from: https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm449865.pdfAccessed July 10, 2017
   Google Scholar
• U.S. Food and Drug Administration, Center for Drug Evaluation and ResearchSummary minutes of the Endocrinologic and Metabolic Drugs Advisory Committee MeetingFDA2015 Available from: https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommit-tee/UCM457467.pdfAccessed July 10, 2017
   Google Scholar
• Institute for Clinical and Economic ReviewPCSK9 inhibitors for treatment of high cholesterol: effectiveness, value, and value-based price benchmarksBoston, MAICER2015 https://icer-review.org/wp-content/uploads/2016/01/Final-Report-for-Posting-11-24-15-1.pdfAccessed July 19, 2017
   Google Scholar
• LubloyAFactors affecting the uptake of new medicines: a systematic literature reviewBMC Health Serv Res20141446925331607
   PubMed Web of Science ®Google Scholar
• Truven Health AnalyticsMarketScan studies: abbreviated bibliographyTruven Health Analytics2017 Available from: http://sites.truvenhealth.com/bibliography/TruvenHealthMarketScanBibliography.pdfAccessed July 10, 2017
   Google Scholar
• BonafedeMMJohnsonBHRichhariyaAGandraSRMedical costs associated with cardiovascular events among high-risk patients with hyperlipidemiaClinicoecon Outcomes Res2015733734526089693
   PubMed Web of Science ®Google Scholar
• LipGYHunterTDQuirozMEZieglerPDTurakhiaMPAtrial fibrillation diagnosis timing, ambulatory ECG monitoring utilization, and risk of recurrent strokeCirc Cardiovasc Qual Outcomes2017101 pii: e002864
   PubMed Web of Science ®Google Scholar
• HwangAYDaveCSmithSMTrends in antihypertensive medication use among US patients with resistant hypertension, 2008 to 2014Hypertension20166861349135427777360
   PubMed Web of Science ®Google Scholar
• FitchKWeismanTEngelTLongitudinal commercial claims-based cost analysis of diabetic retinopathy screening patternsAm Health Drug Benefits20158630030826557224
   PubMedGoogle Scholar
• Writing CommitteeLloyd-JonesDMMorrisPB2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus DocumentsJ Am Coll Cardiol20166819212527046161
   PubMed Web of Science ®Google Scholar
• EllisJJEricksonSRStevensonJGBernsteinSJStilesRAFendrickMASuboptimal statin adherence and discontinuation in primary and secondary prevention populations: should we target patients with the most to gain?J Gen Intern Med200419663864515209602
   PubMed Web of Science ®Google Scholar
• PerreaultSBlaisLLamarreDPersistence and determinants of statin therapy among middle-aged patients for primary and secondary preventionBr J Clin Pharmacol200559556457315842555
   PubMed Web of Science ®Google Scholar
• StoneNJRobinsonJGLichtensteinAH2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice GuidelinesJ Am Coll Cardiol20146325 Pt B2889293424239923
   PubMed Web of Science ®Google Scholar
• GolombBAEvansMAStatin adverse effects: a review of the literature and evidence for a mitochondrial mechanismAm J Cardiovasc Drugs20088637341819159124
   PubMed Web of Science ®Google Scholar
• ICD9data.com [homepage on the Internet]Diagnosis code 272.0. Pure hypercholesterolemiaICD2015 Available from: http://www.icd9data.com/2015/Volume1/240-279/270-279/272/272.0.htmAccessed July 10, 2017
   Google Scholar
• World Health Organization [homepage on the Internet]ICD-10 Version: 2015WHO Available from: http://apps.who.int/classifications/icd10/browse/2015/en#/E70-E90Accessed July 10, 2017
   Google Scholar
• Coding-pro.com [homepage on the Internet]Pure hypercholesterolemia. ICD-10-CM tabular list Available from: http://www.coding-pro.com/icd-10/code_details.php?icd_code=E780Accessed July 10, 2017
   Google Scholar
• GuytonJRBaysHEGrundySMJacobsonTAThe National Lipid Association Statin Intolerance Panel. An assessment by the Statin Intolerance Panel: 2014 updateJ Clin Lipidol201483 SupplS72S8124793444
   PubMed Web of Science ®Google Scholar
• SchulmanKLLameratoLEDalalMRDevelopment and validation of algorithms to identify statin intolerance in a US administrative databaseValue Health2016196852860
   PubMed Web of Science ®Google Scholar
• LiuXKubilisPBussingRWintersteinAGDevelopment of a refill pattern method to measure polypharmacy in administrative claims databasesPharmacoepidemiol Drug Saf201625121407141327528378
   PubMed Web of Science ®Google Scholar
• BushnellGASturmerTWhiteAPredicting persistence to antidepressant treatment in administrative claims data: considering the influence of refill delays and prior persistence on other medicationsJ Affect Disord201619613814726921866
   PubMed Web of Science ®Google Scholar
• TaitelMFensterheimLKirkhamHSekulaRDuncanIMedication days’ supply, adherence, wastage, and cost among chronic patients in MedicaidMedicare Medicaid Res Rev201223 pii: mmrr.002.03.a04
   PubMedGoogle Scholar
• Amgen [homepage on the Internet]Analyses of PCSK9 inhibitor prescription rejection rates demonstrate significant access barriers for appropriate patientsAmgen2017 Available from: https://www.amgen.com/media/news-releases/2017/03/analyses-of-pcsk9-inhibitor-prescription-rejection-rates-demonstrate-significant-access-barriers-for-appropriate-patients/Accessed July 10, 2017
   Google Scholar
• Medscape [homepage on the Internet]WendlingPPCSK9 inhibitor access snarled in red tape, rejectionsMedscape2017 Available from: http://www.medscape.com/viewarticle/877515Accessed May 1, 2017
   Google Scholar
• SaeedAViraniSSJonesPHNambiVZochDBallantyneCMA simplified pathway to proprotein convertase subtilisin/kexin type 9 inhibitor prior authorization approval: A lipid clinic experienceJ Clin Lipidol2017113596599
   PubMed Web of Science ®Google Scholar
• NavarAMTaylorBFievitzEEarly challenges for PCSK9 inhibitor prescriptions and patients: rejections and rates unfilledPresentation to the American College of Cardiology 66th Annual Scientific Session and ExpoMarch 19; 2017Washington, DC
   Google Scholar
• BlueCross BlueShield Federal Employee ProgramPraluent prior approval requestBlueCross BlueShield20161021 Available from: http://www.caremark.com/portal/asset/FEP_Form_Praluent.pdfAccessed July 10, 2017
   Google Scholar
• Defense Health Agency Pharmacy Operations DivisionMTF formu-lary management for PCSK9 inhibitor agent subclassDefense Health Agency Pharmacy Operations Division2016 Available from: https://health.mil/Reference-Center/Fact-Sheets/2017/02/21/Formulary-Management-for-PCSK9-InhibitorsAccessed July 10, 2017
   Google Scholar
• CVS/CaremarkSpecialty guideline management. Praluent (ali-rocumab)Caremark2016 Available from: http://www.caremark.com/portal/asset/Praluent_Policy.pdfAccessed July 10, 2017
   Google Scholar
• United Healthcare Pharmacy, Clinical Pharmacy ProgramsPrior authorization/medical necessity. Repatha (evolocumab)United Healthcare Pharmacy2016 Available from: https://www.united-healthcareonline.com/ccmcontent/ProviderII/UHC/en-US/Assets/ProviderStaticFiles/ProviderStaticFilesPdf/Tools%20and%20Resources/Pharmacy%20Resources/Clinical%20Programs/PA_Med_Nec_Repatha.pdfAccessed July 10, 2017
   Google Scholar
• The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study GroupPrevention of cardiovascular events and death with pravastatin patients with coronary heart disease and a broad range of initial cholesterol levelsN Engl J Med199833919134913579841303
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) CollaborationFulcherJO’ConnellREfficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trialsLancet201538599761397140525579834
   PubMed Web of Science ®Google Scholar
• ChoudhryNKShrankWHFour dollar generics – increased accessibility, impaired quality assuranceN Engl J Med2010363201885188721067379
   PubMed Web of Science ®Google Scholar
• FairmanKACurtissFRHow do seniors respond to 100% cost-sharing for prescription drugs? Quality of the evidence underlying opinions about the Medicare Part D coverage gapJ Manag Care Pharm201117538239221657807
   PubMed Web of Science ®Google Scholar
• Medical Marketing and Media Online [homepage on the Internet]McCaffreyKAmgen launches new Repatha DTC adMM&M2017 Available from: http://www.mmm-online.com/campaigns/amgen-launches-new-repatha-dtc-ad/article/642323/Accessed July 10, 2017
   Google Scholar